| MYGN |
Myriad Genetics, Inc. |
72%
|
Reciprocal relationship from MYGN graph: Reciprocal relationship from ITRM graph: affect supplies of ORLYNVAH™ or product candidates. In addition, our manufacturers are subject to ongoing periodic un… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
affect supplies of ORLYNVAH™ or product candidates. In addition, our manufacturers are subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for … |
| SGIOF |
Shionogi & Co., Ltd. |
72%
|
Reciprocal relationship from SGIOF graph: Reciprocal relationship from ITRM graph: sfer funds from our investment accounts to new operating accounts on a timely basis sufficient to meet our operating… |
| SGIOF |
Shionogi & Co., Ltd. |
72%
|
sfer funds from our investment accounts to new operating accounts on a timely basis sufficient to meet our operating expense obligations. Changes in and uncertainty surrounding trade policy, includin… |
| ALICE-CORPORATION-PTY-LTD |
ALICE-CORPORATION-PTY-LTD |
62%
|
affect supplies of ORLYNVAH™ or product candidates. In addition, our manufacturers are subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for … |
| BGI-GROUP-BGI-GENOMICS-CO-LTD |
BGI-GROUP-BGI-GENOMICS-CO-LTD |
62%
|
ly target biotechnology companies that have been identified on the so-called 1260H List by the U.S. Department of Defense as Chinese Military Companies Operating in the United States. This list curre… |
| BMY |
Bristol-Myers Squibb Company |
62%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from ITRM graph: Reciprocal relationship from BMY graph: Reciprocal relationship from ITRM graph: Reciprocal relationship from BMY grap… |
| CHAMBER-BRISTOL-MYERS-SQUIBB-COMPANY |
CHAMBER-BRISTOL-MYERS-SQUIBB-COMPANY |
62%
|
early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health … |
| CHEVRON-U-S-A-INC |
CHEVRON-U-S-A-INC |
62%
|
d to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents covering our… |
| CIPLA-LIMITED |
CIPLA-LIMITED |
62%
|
sfer funds from our investment accounts to new operating accounts on a timely basis sufficient to meet our operating expense obligations. Changes in and uncertainty surrounding trade policy, includin… |
| CO-LLC |
CO-LLC |
62%
|
ed with operating as a public company, including legal, accounting, investor relations and other expenses. As a result, we will require additional capital to fund our operations, to continue to devel… |
| CO-LTD |
CO-LTD |
62%
|
sfer funds from our investment accounts to new operating accounts on a timely basis sufficient to meet our operating expense obligations. Changes in and uncertainty surrounding trade policy, includin… |
| CORNER-POST-INC |
CORNER-POST-INC |
62%
|
d to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents covering our… |
| ITERUM-THERAPEUTICS-INTERNATIONAL-LIMITED |
ITERUM-THERAPEUTICS-INTERNATIONAL-LIMITED |
62%
|
nce our operations and generate revenue from product sales, currently depend entirely on the development and commercialization of ORLYNVAH™. Following receipt of FDA approval for ORLYNVAH™ in October… |
| LIFE-SCIENCES-FUND-II-LLC |
LIFE-SCIENCES-FUND-II-LLC |
62%
|
ain compliance with the other Nasdaq listing requirements or be successful in appealing any delisting determination. Although we have been able to regain compliance with Nasdaq listing requirements w… |
| MGI-TECH-CO-LTD |
MGI-TECH-CO-LTD |
62%
|
ly target biotechnology companies that have been identified on the so-called 1260H List by the U.S. Department of Defense as Chinese Military Companies Operating in the United States. This list curre… |
| NATURAL-RESOURCES-DEFENSE-COUNCIL-INC |
NATURAL-RESOURCES-DEFENSE-COUNCIL-INC |
62%
|
d to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents covering our… |
| OFFSHORE-MASTER-FUND-LP-SARISSA-CAPITAL-CATAPULT |
OFFSHORE-MASTER-FUND-LP-SARISSA-CAPITAL-CATAPULT |
62%
|
nce our operations and generate revenue from product sales, currently depend entirely on the development and commercialization of ORLYNVAH™. Following receipt of FDA approval for ORLYNVAH™ in October… |
| PROMETHEUS-LABORATORIES-INC |
PROMETHEUS-LABORATORIES-INC |
62%
|
affect supplies of ORLYNVAH™ or product candidates. In addition, our manufacturers are subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for … |
